Testing a Biometric Identification System to Improve Malaria Vaccine Completion
NCT07261280 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4715
Last updated 2025-12-03
Summary
Receiving all four doses of the malaria vaccine can significantly protect children against malaria illness, hospitalization, and death. However, in Ghana, only 46% of children complete the full vaccination sequence. More broadly, many children in Ghana do not receive the full set of recommended pediatric vaccinations. To address this, Simprints, in collaboration with Ghana Health Services, will implement a digital vaccination record system linked to biometrics. This system will automatically identify children who are behind on their vaccination schedule, providing health workers with information to prioritize community outreach. Additionally, it will send voice message reminders to caregivers to improve compliance. A cluster-randomized controlled trial (c-RCT) will be conducted in the Oti region to measure the impact of this innovation on the proportion of children completing malaria and routine vaccination schedules.
Conditions
- Vaccination
Interventions
- BEHAVIORAL
-
HEALTH FACILITY INTERVENTION
Health facilities randomized in treatment clusters will be provided with a digital vaccination record system (e-tracker) linked to biometrics (facial recognition) of caregivers (if child is below 6 months) or of children (if child is above 6 months). With the support of Ghana Health Services, Simprints will train CHWs on digital vaccination record system (e-tracker) and biometrics. Simprints will also provide Technical Assistance to CHWs for the duration of the study.
- BEHAVIORAL
-
INDIVIDUAL INTERVENTION
Caregivers (if child is below 6 months) or children (if child is above 6 months) living in communities in the catchment areas of health facilities randomized in treatment clusters will be registered at the community level into the e-tracker and biometrics (facial recognition), and caregivers of children who are due for or missed vaccination will receive voice message appointment reminders if they provided a phone number during the registration in biometrics. Reminders will be sent before a child is due a visit to receive vaccination, as well as after a child missed his due visit.
Sponsors & Collaborators
-
University of Ghana
collaborator OTHER -
Harvard School of Public Health (HSPH)
collaborator OTHER - lead OTHER
Principal Investigators
-
Elisa Maria Maffioli, PhD · University of Michigan
-
Jessica Cohen, PhD · Harvard University
-
Chris Guure · University of Ghana
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 15 Years
- Max Age
- 49 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-10-15
- Primary Completion
- 2027-12-31
- Completion
- 2027-12-31
Countries
- Ghana
More Related Trials
-
Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant
NCT00320658 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313
NCT02532049 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
NCT07036159 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
NCT03276962 ·Status: COMPLETED ·Phase: PHASE2
-
Preventing the Spread of Malaria in Mali
NCT01360112 ·Status: COMPLETED
-
Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Don gu Bougou, Mali
NCT00341783 ·Status: TERMINATED
-
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
NCT06958198 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya
NCT00666380 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909
NCT01351948 ·Status: COMPLETED ·Phase: PHASE1
-
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
NCT02098590 ·Status: COMPLETED ·Phase: NA
-
A Study of the Safety and Effectiveness of Two New Malaria Vaccines
NCT01003314 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Systems Biology Approach to Malaria Immunity
NCT03014258 ·Status: COMPLETED ·Phase: PHASE1
-
Infant Malaria Vaccine Schedule Optimization
NCT06879327 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
NCT06320535 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1
NCT01739036 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
NCT02639299 ·Status: RECRUITING
-
Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires
NCT01214876 ·Status: COMPLETED
-
Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP
NCT01364883 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
NCT05155579 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
NCT06080243 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant
NCT06549257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults
NCT03162614 ·Status: COMPLETED ·Phase: PHASE2
-
Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
NCT02080026 ·Status: COMPLETED ·Phase: NA
-
L9LS in Women of Childbearing Potential in Mali
NCT07060508 ·Status: RECRUITING ·Phase: PHASE2
-
Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines
NCT00443131 ·Status: COMPLETED ·Phase: PHASE2